No Data
No Data
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
Novo Holdings Participates in €23 Million Series A for Tribune Therapeutics to Advance Next-generation Anti-fibrotic Therapies
Marty Makary and Jay Bhattacharya Clear Senate Hurdles to Lead FDA and NIH
Step Aside, Novo Nordisk. This Is Europe's No. 1 Company Now. -- Barrons.com
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Novo-Nordisk A/S has acquired the licensing of a new weight loss drug from a Guangdong pharmaceutical factory, targeting the strength of Innovative Drugs in China.
① Due to the next-generation weight loss drug CagriSema's experimental data failing to convince the market, Novo-Nordisk A/S's stock price has halved in the past year; ② Novo-Nordisk A/S announced on Monday a deal to acquire the overseas rights to China's Innovative Drugs UBT251 for up to 2 billion USD; ③ Analysts expect UBT251 to show data comparable to Eli Lilly and Co's next-generation weight loss drug Retatrutide.